Dr. Dewil joins ICON from BARC Global Central Laboratories, where he held the role of Chief Operating Officer, responsible for the daily operation of BARC's worldwide laboratory network. Prior to this, Dr. Dewil spent six years at General Electric Medical Systems, where he had global responsibility for the company's Interventional Imaging products, having previously been a senior business development manager in Europe, Middle East and Africa. Dr Dewil has also held management positions at Schering AG, Medvision and Sonotron NV.
Dr. Dewil received his medical degree from Université Catholique de Louvain, Belgium, and also holds a Doctorate in Medicine from St. Petersburg University, Russia.
"I am delighted to welcome Dr. Dewil to the management team at ICON Central Laboratories," commented Bob Scott-Edwards, President, ICON Central Laboratories. "His comprehensive knowledge of the central laboratory industry, coupled with his invaluable experience in process improvement and quality management will be vital as we continue to expand our global footprint."
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full service, global central laboratory services from core facilities in New York, Dublin and Singapore, as well as through quality affiliate laboratories in China and Japan. An extensive test menu of safety, esoteric and custom-developed assays, including global flow cytometry, is complemented by dedicated, sponsor-specific project teams and a single, comprehensive database for each study as well as a user-friendly, web-based, secure remote data access system. ICON Central Laboratories also offers a unique service to manage and compile laboratory data when a client's study requires the use of local laboratories.
For more information, visit www.icolabs.com.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 5500 development projects and consultancy engagements across all major therapeutic areas. ICON currently has over 6500 employees, operating from 71 locations in 38 countries.
Further information is available at www.iconplc.com